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Abstract: Clinically, 3 distinct stages of diabetic foot infection may be recognized: localized 
infection, spreading infection and severe infection. Each of these presentations may be 
complicated by osteomyelitis. Infection can be caused by Gram-positive aerobic, and Gram-
negative aerobic and anaerobic bacteria, singly or in combination. The underlying principles 
are to diagnose infection, culture the bacteria responsible and treat aggressively with antibiotic 
therapy. Localized infections with limited cellulitis can generally be treated with oral antibiotics 
on an outpatient basis. Spreading infection should be treated with systemic antibiotics. Severe 
deep infections need urgent admission to hospital for wide-spectrum intravenous antibiotics. 
Clinical and microbiological response rates have been similar in trials of various antibiotics and 
no single agent or combination has emerged as most effective. Recently, clinical and microbio-
logical outcomes for patients treated with ertapenem were equivalent to those for patients treated 
with piperacillin/tazobactam. It is also important to judge the need for debridement and surgery, 
to assess the arterial supply to the foot and consider revascularization either by angioplasty or 
bypass if the foot is ischemic. It is also important to achieve metabolic control. Thus infection 
in the diabetic foot needs full multidisciplinary treatment.
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Introduction
At some time in their life, 15% of people with diabetes develop foot ulcers. Eighty-five 
percent of amputations are preceded by an ulcer1 and there is an amputation every 
30 seconds throughout the world.2 The main reason for this is that foot ulcers are 
highly susceptible to infection.3 This may spread rapidly leading to overwhelming 
tissue destruction and the need for amputation. Guidelines on the Diagnosis and 
Treatment of Diabetic Foot Infections have been issued from the Infectious Diseases 
Society of America (IDSA)4 and also by The International Working Group on the 
Diabetic Foot, which produced its International Consensus Guidelines on Diagnosing 
and Treating Infected Diabetic Foot in 20035 and recently guidelines for the treatment 
of Diabetic Foot Osteomyelitis in 2007.6,7 New developments have recently been 
reviewed by Lipsky.8
Classification of infection
Various classifications of infection exist and the ISDA has staged infection from mild 
to moderate to severe.4 Mild infection is characterized by the presence of 2 manifesta-
tions of inflammation (purulence, or erythema, pain, tenderness, warmth or induration), 
with cellulitis/erythema extending less than 2 cm around the ulcer, and infection is Vascular Health and Risk Management 2009:5 950
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limited to the skin or superficial subcutaneous tissue with no 
other local complications or systemic illness. In moderate 
infection, the patient has one of the following characteristics: 
cellulitis extending 2 cm, lymphangitic streaking, spread 
beneath the superficial fascia, deep-tissue abscess, gangrene, 
and involvement of muscle, tendon, joint or bone, but is 
systemically well and metabolically stable. In severe infection, 
the patient has systemic toxicity or metabolic instability 
(eg, fever, chills, tachycardia, hypotension, confusion, 
vomiting, leukocytosis, acidosis, severe hyperglycemia, or 
azotemia). Validation of the IDSAs diabetic foot infection 
classification system has been reported in a longitudinal 
study of 1666 persons with diabetes.9 There was an observed 
trend toward an increased risk for amputation, higher-level 
amputation and lower extremity-related hospitalization with 
increasing infection severity. Other classifications include 
limb threatening and non-limb threatening infections.10
Clinical presentation of infection
Clinically, 3 distinct stages of diabetic foot infection may 
be recognized: localized infection, spreading infection and 
severe infection. Each of these presentations may be com-
plicated by osteomyelitis.11
Localized infection
Localized infection refers to infection in the ulcer bed 
or immediately surrounding skin. This may present with 
purulent discharge and surrounding erythema, but often the 
classical signs of infection are diminished by the presence 
of neuropathy and ischemia (Figure 1). Thus the signs of 
infection may be very subtle. Galen’s classical signs and 
symptoms of redness, heat, pain and loss of function may 
not be evident. However, early warning signs of infection 
and signs of deterioration should be searched for with great 
assiduity in all diabetic foot patients, especially those with 
breaks in the skin.
Spreading infection
Sepsis has progressed to give signs of spreading infection 
emanating from the ulcer such as diffuse spreading erythema, 
edema, lymphangitis and lymphadenitis, and in addition, 
there will usually be local signs of infection as described 
above (Figure 2). Systemic symptoms and signs may be 
present when the foot has extensive diffuse cellulitis, The 
portal of entry of infection may be a corn, callus, blister, 
fissure or any other skin break.
Severe infection
This refers to ulcers with extensive deep soft tissue 
infection. In the presence of neuropathy, pain and throb-
bing may be absent, but if present this is a danger sign, 
usually indicating serious infection with pus within the 
tissues. Palpation may reveal fluctuance, suggesting 
abscess formation. There may be bulging of the plantar 
surface of the foot. Discrete abscesses are relatively 
uncommon in the infected diabetic foot. Often there is a 
generalized sloughing of the ulcer and surrounding subcu-
taneous tissues which eventually liquefy and disintegrate. 
In late infection, there is swelling and a brawny effect. 
The tissues may be sloughing and breaking down and 
blistered, or fluctuant, and often never recover but need 
Figure 1 infection in ulcer bed with mild surrounding erythema. Figure 2 Spreading cellulitis.Vascular Health and Risk Management 2009:5 951
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surgical removal. Severe infection can also present as a 
bluish-purple discoloration when there is inadequate supply 
of oxygen to the soft tissues leading to gangrene (Figure 3). 
This is caused by increased metabolic demands of infection 
and a reduction of blood flow to the skin, secondary to a 
septic vasculitis of the cutaneous circulation. Purple blebs 
may indicate subcutaneous necrosis. Blue discoloration can 
occur in both the neuropathic and also the neuroischemic 
foot, particularly in the toes, and in the neuroischemic 
foot must not be automatically attributed to worsening 
ischemia.
This stage may also be associated with septicemia, with 
the patient presenting with hypotension and organ failure. 
Signs of severe infection may include drowsiness shivering, 
tachycardia, hypotension, reduced body temperature (35 
°C) or high fever (40 °C). However, systemic signs and 
symptoms are notoriously absent in many severe infections 
of the diabetic foot. Among patients hospitalized for late 
infections only 12% to 35% have significant fever and only 
50% of episodes of severe cellulitis will provoke a fever 
or leucocytosis. However, when fever is present it usually 
indicates a severe infection and the deep spaces of the foot 
are usually involved with tissue necrosis, severe cellulitis 
and possible bacteremia.
Osteomyelitis
Usually osteomyelitis will present in association with 
ulceration and soft tissue infection. Clinically, osteomyelitis 
may be suspected when a sterile probe inserted into the 
base of the ulcer penetrates to bone. This may happen in an 
apparently clean, uninfected ulcer, but osteomyelitis must 
still be suspected. It may present as obvious fragmentation 
of the bone within the ulcer bed, which is easily visible. 
Chronic osteomyelitis of a toe has a swollen, red, sausage-like 
appearance. It is most commonly diagnosed on X-ray. Loss 
of cortex, fragmentation and bony destruction on X-ray are 
signs of osteomyelitis. These changes may take 10 to 14 days 
to develop. MRI is the best imaging technique to diagnose 
osteomyelitis and can demonstrate edema and abscesses in 
bone. However bone edema may also be present in Charcot’s 
osteoarthropathy. Osteomyelitis may be confirmed in theory 
by a positive bone culture or bone biopsy showing bone 
death, inflammation and repair. Bone biopsy is often not 
very practical, and then the diagnosis is made on clinical 
and radiological grounds.
Microbiology of the diabetic foot
The microbiology of the diabetic foot is unique. Infection 
can be caused by Gram-positive aerobic, Gram-negative 
aerobic and anaerobic bacteria, singly or in combination. 
As there may be a poor immune response of the diabetic 
patient, even bacteria normally regarded as skin commen-
sals may cause severe tissue damage. Furthermore, when 
Gram-negative bacteria such as Citrobacter, Serratia, 
Pseudomonas and Acinetobacter are isolated from a deep 
ulcer swab or curettings they should not, be regarded as 
automatically insignificant. Severe infections are often 
polymicrobial and both Gram-positive and Gram-negative 
organisms are present together with anaerobes. Severe 
subcutaneous infection by Gram-negative and anaerobic 
organisms produces gas which may be detected by palpating 
crepitus on the lower limb and can be seen on X-ray. The 
presence of gas does not automatically mean that the classical 
gas gangrene organism Clostridium perfringens is present. 
The most common cause is a synergism of Gram-negative 
organisms and anaerobes although Staphylococcus aureus 
can also lead to non-clostridial necrosis.
In a recent review of the microbiology of 427 positive 
cultures from moderate to severe infections,12 infections 
were typically polymicrobial, and almost half included 
anaerobes; 84% were polymicrobial, 48% grew only aerobes, 
43.7% had both aerobes and anaerobes, and 1.3% had only 
anaerobes. Cultures yielded an average of 2.7 organisms 
per culture (range 1 to 8) for aerobes and 2.3 organisms 
per culture (range 1 to 9) for anaerobes. The main aerobic 
organisms were oxacillin-susceptible S. aureus (14.3%), 
oxacillin-resistant S. aureus (4.4%), coagulase-negative 
Staphylococcus spp. (15.3%), Streptococcus spp. (15.5%),  Figure 3 infective necrosis of second toe.Vascular Health and Risk Management 2009:5 952
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Enterococcus spp. (13.5%), Corynebacterium spp. (10.1%), 
members of the family Enterobacteriaceae (12.8%), and 
Pseudomonas aeruginosa (3.5%). The predominant anaer-
obes were Gram-positive cocci (45.2%), Prevotella spp. 
(13.6%), Porphyromonas spp. (11.3%), and the Bacteroides 
fragilis group (10.2%).
It is important to have a working knowledge of the 
principal bacteria and their local antibiotic sensitivities, 
including awareness of the prevalence of resistant organisms. 
However, in every patient, individual sensitivities of each 
organism isolated on culture should be sought to guide 
rational antibiotic therapy. When the patient initially presents, 
microbiology data are not available and empirical therapy 
will need to be started and there should be close co-operation 
between the microbiology laboratory and the diabetic foot 
service.
S. aureus
S. aureus is the commonest pathogen in the diabetic foot 
and flucloxacillin is the ideal treatment. Ertythromycin and 
clarithromycin can also be used. Clindamycin is usually 
effective but it is necessary to be aware of antibiotic-induced 
colitis especially in the elderly and postoperative patients. 
Rifampicin and fucidin are also good antistaphylococcal 
agents, but they should not be given alone as resistance will 
develop rapidly. They should each be accompanied by a 
further antistaphylococcal agent.
Methicillin-resistant S. aureus (MRSA)
MRSA is associated with the whole spectrum of clinical 
presentations of diabetic foot infections and commonly 
occurs in patients who have been in hospital. It can be 
simply a commensal with no signs of invasive infection 
but it can also cause severe infections, osteomyelitis and 
bacteremia. Since colonization precedes infection, contact 
with other patients with MRSA is a risk factor. Other risk 
factors include repeated hospitalizations, lengthy hospital 
stays, prior antimicrobial therapy and the presence of 
surgical wounds.The frequency of MRSA infections is 
increasing in the diabetic foot.13 In a study investigating the 
prevalence of MRSA in infected and uninfected diabetic 
foot ulcers of 84 patients with diabetes, S. aureus was the 
most common pathogen among the Gram-positive bacteria 
isolated from ulcers, and almost 50% of S. aureus isolates 
were MRSA. The prevalence of MRSA was significantly 
higher in patients with infected foot ulcers.14 However, 
MRSA infections are not necessarily more pathogenic than 
conventional S. aureus infections. They do frequently cause 
more extensive tissue destruction because they are often 
not diagnosed until late. This is an important reason to 
maintain frequent bacteriological surveillance on all ulcers 
in diabetic feet. Hospital acquired MRSA is multiresistant 
to all beta lactams antibiotics and to a varying extent 
macrolides, fluoroquinolones and aminoglycosides, but are 
usually sensitive to gentamicin.
MRSA may be also be acquired in the community.15 This 
has been associated with outbreaks in groups of individuals 
with close contact in institutions such as prisons which can 
then be transferred to hospitals. These MRSA do not have the 
multiresistance of the hospital acquired MRSA but neverthe-
less can rapidly progress to severe infections. Approximately 
two-thirds possess the Panton-Valentine leukocidin toxin, 
which acts to form pores in the cell membrane of mono-
nuclear cells and polymorphonuclear cells and can lead to 
severe tissue necrosis.
MRSA can lead to invasive infection and in these 
circumstances it is best to give vancomycin intravenously 
with dosage to be adjusted according to serum levels, or 
teicoplanin. These antibiotics may need to be accompanied by 
either sodium fusidate or rifampicin orally. New antimicrobial 
agents have become available.16 Linezolid is active against 
MRSA and has good soft tissue and bony penetration.17,18 It is 
well absorbed. It is necessary, however, to check the platelet 
count regularly as there may be some marrow suppression 
with this antibiotic. Courses should not exceed 28 days. The 
combination of antibiotics quinupristin and dalfopristin 
can be used when an MRSA infection has not responded to 
other antibacterials. Daptomycin and tigecycline may also 
be used in MRSA infections.19 MRSA can also be treated 
with clindamycin but sensitivity needs to be confirmed as 
MRSA resistance to clindamycin has emerged. If MRSA is 
isolated in localized infections, oral therapy can be given with 
two of the following: sodium fusidate 500 mg tds, rifampicin 
300 mg tds, trimethoprim 200 mg bd or doxycycline 100 mg 
daily, according to sensitivities.
Streptococcus group   A, B, C, E, F and G
Streptococcus group B is being increasingly recognized as 
an important pathogen in the diabetic foot although C, E, F 
and G can also infect the foot.20 Streptococcus group A rarely 
causes infection but when it does, it causes a severe blistering 
cellulitis and tissue destruction. The Streptococcus milleri 
group of organisms are also beta hemolytic streptococci that 
can cause abcesses in the foot. Streptococci can be treated 
with amoxicillin. Clindamycin, rifampicin and erythromycin 
may also be also active against streptococci.Vascular Health and Risk Management 2009:5 953
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Enterococcus
Enterococcus faecalis is rarely pathogenic. It may be 
selected out by cephalosporin treatment. If it is causing 
definite infection then it may be treated with amoxicillin or 
vancomycin. Vancomycin-resistant enterococcus (VRE) is a 
problem with hospitalized patients previously treated with 
antibiotics (especially patients in renal failure). It is necessary 
to assess whether it is actually causing tissue destruction 
as it is normally not pathogenic. However, in the immuno-
compromised diabetic patient, especially in the ischemic foot, 
it may be responsible for infection and should therefore be 
treated with appropriate antibiotics as suggested by culture 
sensitivities. Enterococcus faecium may need vancomycin 
treatment and quinupristin/dalfopristin and linezolid are 
useful for vancomycin-resistant E. faecium infections.
C. perfringens
C. perfringens is a Gram-positive bacillus that can produce 
many toxins including including alpha-toxin. It is well known 
for causing clostridial myonecrosis or gas gangrene, although 
this is more often caused by non-clostridial organisms, 
namely Gram-negatives and anaerobes.
Anaerobes
These are commonly found in deep infections but anaerobes 
are also a feature of many chronic wounds even when they are 
superficial. They are also associated with necrotic wounds. 
Anaerobes can act synergistically with Gram-positive and 
Gram-negative aerobes to cause severe tissue destruction as 
well as synergistic and gas gangrene. The latter is traditionally 
associated with C. perfringens but is now usually caused by 
synergy between Gram-negative organisms and anaerobes.
Metronidazole is the treatment of choice. Clindamycin 
and co-amoxiclav (amoxicillin/clavulanic acid) also have anti-
anaerobic activity. Meropenem, piperacillin/tazobactam and 
ertapenem are also active against anaerobes. Gas in the soft 
tissues of an ill diabetic patient presenting with cellulitis 
raises the serious possibility of synergistic gangrene. 
In such circumstances, clindamycin would be preferable to 
flucloxacillin because of its effect on protein, and hence toxin 
production.
Enterobacteriaceae
The Enterobacteriaceae, which include Klebsiella, Escherichia 
coli, Proteus, Enterobacter, Citrobacter, Serratia and other 
Gram-negative bacteria, can be definitely pathogenic in the 
diabetic foot especially when they are in a pure growth or 
as part of a polymicrobial deep infection. Oral agents that 
are available to treat these Gram-negatives are ciprofloxacin 
and other quinolones and trimethoprim. Parenteral agents 
include ceftazidime, aminoglycosides, meropenem, 
piperacillin/tazobactam, ticarcillin/clavulanate, tigecycline 
and ertapemem. It is crucial to obtain sensitivity patterns 
with Gram negative organisms and not depend on empirical 
therapy alone.
Recently, Gram-negative bacteria have acquired various 
resistance patterns through the development of certain 
enzymes and this is relevant to the choice of antibiotic 
therapy. Organisms have developed extended spectrum 
beta-lactamases which are known as ESBLs. By this means, 
they have developed resistance to extended-spectrum (third 
generation) cephalosporins (eg, ceftazidime, cefotaxime, 
ceftriaxone) but not to carbapenems (eg, meropenem 
or ertapenem). ESBL enzymes are most commonly 
produced by E. coli, Klebsiella pneumoniae and Entero-
bacter aerogenes. Another group of lactamases are AmpC 
beta-lactamases which are typically encoded on the 
chromosomes of many Gram-negative bacteria including 
Citrobacter, Serratia and Enterobacter spp. where expres-
sion is usually inducible. Thus, organisms considered 
susceptible by in vitro testing can become resistant during 
treatment with cephalosporins. Carbapenems are the only 
reliable beta-lactam drugs for the treatment of severe 
Enterobacter infections.
Pseudomonas
There are many members of the genus Pseudomonas, and 
P. aeruginosa is an important human opportunist bacterium 
in the diabetic foot. It can be responsible for a spectrum 
of presentations from superficial colonization of ulcers to 
extensive tissue damage, including osteomyelitis, septic 
arthritis and bacteremia. It may be sensitive to ciprofloxacin 
as an oral agent. Otherwise parenteral therapy is necessary 
and includes ceftazidime, aminoglycosides, meropenem, 
piperacillin/tazobactam, and ticarcillin/clavulanate.
Stenotrophomonas maltophilia
Stenotrophomonas maltophilia is the type species of 
Stenotrophomonas. This Gram-negative bacterium was 
initially classified as Pseudomonas maltophilia. It is 
resistant to many broad-spectrum antibiotics (including 
all carbapenems), and is usually resistant to aminoglyco-
sides, antipseudomonal penicillins and third-generation 
cephalosporins. It is often acts as a colonizer. However, 
if isolated from a purulent wound, S. maltophilia may be 
the cause of the patient’s wound infection. Many strains of Vascular Health and Risk Management 2009:5 954
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S. maltophilia are sensitive to co-trimoxazole, ticarcillin/
clavulanate and colomycin.
Treatment
The development of infection constitutes a foot care 
emergency, which requires referral to specialized foot-care 
team within 24 hours. The underlying principles are to 
diagnose infection, culture the bacteria responsible, treat 
aggressively with antibiotic therapy and consider the need for 
debridement and surgery. Usually, therapy is commenced with 
wide spectrum therapy which is then focused according to 
the microbiology culture results. It is also important to assess 
the arterial supply to the foot and consider revascularization 
either by angioplasty or bypass if the foot is ischemic. It is 
also important to achieve metabolic control. Thus infection in 
the diabetic foot needs full multidisciplinary treatment. The 
team managing these infections should preferably include, 
or have ready access to, an infectious diseases specialist or 
a medical microbiologist.
When managing these very difficult and unstable feet, 
decision making should be guided by symptoms and signs 
of infection, results of properly taken wound swabs and 
tissue cultures and past and present knowledge of individual 
patients. While devising a management plan for the dif-
ferent presentations of infection it is important to address 
these questions: Does the patient need oral or systemic 
antibiotics? Does the patient need surgery? However, 
evidence from systematic reviews to inform these decisions 
is limited.21,22
In a systematic review of the evidence for antimicro-
bial interventions for foot ulcers in diabetes, 23 studies 
were assessed for the effectiveness or cost-effectiveness 
of antimicrobial agents: intravenous antibiotics (n = 8); 
oral antibiotics (n = 5); topical antimicrobials (n = 4); 
subcutaneous granulocyte-colony stimulating factor 
(G-CSF) (n = 4); ayurvedic preparations (n = 1): and 
sugar vs antibiotics vs standard care (n = 1). The review 
concluded that the trials were small and too dissimilar to 
be pooled. There was no strong evidence for any particu-
lar antimicrobial agent for the prevention of amputation, 
resolution of infection, or ulcer healing. Clinical clues to 
guide antibiotic selection have recently been reviewed.23 
Initial antibiotic therapy for diabetic foot infections is 
usually empirical but several principles may aid to avoid 
selecting either an unnecessarily broad or inappropriately 
narrow regimen. Firstly, clinically severe infections require 
broad-spectrum therapy, while less severe infections may 
not. Second, aerobic Gram-positive cocci, particularly 
S. aureus (including MRSA for patients at high-risk) 
should always be covered. Third, therapy should also 
be aimed at aerobic Gram-negative pathogens if the 
infection is chronic or has failed to respond to previous 
antibiotic therapy. Fourth, anti-anaerobic agents should 
be considered for necrotic or gangrenous infections on 
an ischemic limb.
Localized infection
Localized infections can generally be treated with oral 
antibiotics on an outpatient basis. Several antibiotics have 
been shown to be effective in clinical trials including cepha-
lexin, clindamycin, ciprofloxacin, ofloxacin, levofloxacin, 
clindamycin, pexiganan and linezolid.24 However, no single 
drug or combination of agents appears to be better than 
others. Antibiotics should be consistent with local antibiotic 
policies and initially, commonly used first line antibiotics 
should be prescribed and new antibiotics reserved for later 
use for resistant organisms.
If MRSA is grown and there are no local or systemic signs 
of infection, topical mupirocin 2% ointment (if sensitive) may 
be used. If MRSA is grown and accompanied by local signs 
of infection, oral therapy with two of the following should be 
considered: sodium fusidate, rifampicin, trimethoprim and 
doxycycline, according to sensitivities, together with topical 
mupirocin 2% ointment.
Spreading infection
This condition should be treated with systemic antibiotics. 
It can sometimes be treated at the patient’s home with intra-
muscular or intravenous antibiotics under close surveillance 
by relatives and frequent visits from the community nurse. 
In these circumstances, ceftriaxone may be given intramus-
cularly together with metronidazole orally. Ceftriaxone has 
been demonstrated to be just as efficacious as ticarcillin/ 
clavulanate.25 However, where the cellulitis is extensive, or 
in the ischemic foot, intravenous antibiotics and hospital 
admission will be needed at the outset for patients with 
spreading infection.
At initial presentation, it is important to prescribe a wide 
spectrum of antibiotics for three reasons:
a.  it is impossible to predict the number and type of 
organisms from the clinical presentation
b.  there is no way of predicting who will develop a rapidly 
ascending infection which becomes limb-threatening 
and even life-threatening
c.  diabetic patients are immunosuppressed. The neuropathy 
and ischemia of the diabetic foot reduces the local Vascular Health and Risk Management 2009:5 955
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resistance to invading bacteria. As is attributed to Louis 
Pasteur: “The germ is nothing. It is the terrain in which 
it grows that is everything.”
Severe infection
Severe infections need urgent admission to hospital for 
wide spectrum intravenous antibiotics. Indications for 
urgent surgical intervention are infected sloughy tissue, 
localized fluctuance and expression of pus, crepitus with 
gas in the soft tissues on X-ray and purplish discoloration 
of the skin indicating subcutaneous necrosis. Infected tissue 
should be sent for culture after debridement. Clinical and 
microbiological response rates have been similar in trials of 
various antibiotics and no single agent or combination has 
emerged as most effective. Recently, clinical and microbio-
logical outcomes for patients treated with ertapenem were 
equivalent to those for patients treated with piperacillin/
tazobactam, in a randomized, double-blinded, multicenter 
trial in adults (n = 586) with diabetes and a foot infection 
classified as moderate-to-severe and requiring intravenous 
antibiotics.26 For further discussion of the role of ertapenem 
and piperacillin/tazobactam see below.
It is important to have a practical approach to the treatment 
of severe infections reserving complex new antibiotics for 
resistant organisms, as described in the approach to mild 
infections. Ideally, the diabetic patient with severe cellulitis 
needs admission for intravenous antibiotics. If admission is 
not possible, then ceftriaxone may be given intramuscularly 
together with metronidazole orally. Ceftriaxone has 
been demonstrated to be just as efficacious as ticarcillin/
clavulanate. On review as an outpatient, if cellulitis is 
controlled, ceftriaxone intramuscularly and metronidazole 
orally should be continued and the patient reviewed one 
week later. If cellulitis is increasing, then the patient 
should be admitted for intravenous antibiotics. A standard 
broad spectrum, parenteral, quadruple antibiotic therapy 
(flucloxacillin, amoxicillin, metronidazole and ceftazidime) 
has been developed and used sucessfully at King’s College 
Hospital, London for the last 15 years for the treatment of 
severe limb threatening infections in a variety of diabetic 
patients with varying levels of associated co-morbidity such 
as lower limb ischemia and/or renal impairment.
Quadruple therapy may be used including amoxycillin, 
flucloxacillin, metronidazole and ceftazidime.11 If the patient 
is allergic to penicillin, amoxycillin and flucloxacillin 
should be replaced with vancomycin (with doses adjusted 
according to serum levels). Furthermore, if the patient is 
known to have recent MRSA infection, then vancomycin 
should also be substituted for amoxicillin and flucloxacillin. 
On admission the foot should be urgently assessed as to the 
need for surgical debridement. On follow-up, the infected 
foot should inspected daily to gauge the initial response to 
antibiotic therapy. Appropriate antibiotics should be selected 
when sensitivities are available. If MRSA is isolated, then 
vancomycin (dosage to be adjusted according to serum levels) 
or teicoplanin should be given. These antibiotics may need to 
be accompanied by a further appropriate oral antibiotic such 
as sodium fusidate or rifampicin. When the signs of cellulitis 
have resolved intravenous antibiotic therapy can be changed 
to the appropriate oral therapy, usually any two of sodium 
fusidate, rifampicin trimethoprim or doxycycline.
Osteomyelitis
Osteomyelitis can complicate any of the above infective 
presentations.
initial treatment
When diagnosis of osteomyelitis is made clinically, 
an empirical regime with good bone penetration should 
be given such as rifampicin 300 mg tds and ciprofloxacin 
500 mg bd. On review, antibiotic selection is guided by the 
results of deep swabs tissue biopsy or bone culture. Some 
centers base their antibiotic selection on bone culture results 
alone. However, sinus tract or ulcer culture results may be 
helpful. A bone biopsy may be difficult to obtain and is not 
without risk in the neuroischemic foot. It is useful to choose 
antibiotics with good bone penetration, such as sodium 
fusidate 500 mg tds, rifampicin 300 mg tds, clindamycin 
300 mg tds and ciprofloxacin 500 mg bd.
Follow-up plan
Oral antibiotics should be given for at least 12 weeks. 
Parenteral therapy has in the past been given for 4 to 6 weeks 
followed by oral therapy. However, it may be possible to limit 
the parenteral therapy to 2 weeks and follow this with appro-
priate oral antibiotics (if the infected bone is resected then a 
shorter course of antibiotics such as 4 weeks may be necessary). 
Conservative therapy is often successful, and is associated 
with resolution of cellulitis and healing of the ulcer.
Antibiotics used mainly against 
Gram-positive organisms
Amoxicillin
This antibiotic is active against streptococci but is inactivated 
by penicillinases that are produced by S. aureus and by Gram-
negative bacteria such as E. coli.Vascular Health and Risk Management 2009:5 956
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Co-amoxiclav
This is a combination of amoxicillin and clavulanic acid. 
The latter is a beta-lactamase inhibitor, thus widening the 
spectrum of activity of co-amoxiclav against beta lactamase 
producing bacteria that are resistant to amoxicillin including 
staphylococci, anaerobes and Gram-negative bacteria. The 
risk of liver toxicity is 6 times greater with co-amoxiclav 
compared with amoxicillin.
Flucloxacillin
This antibiotic is not destroyed by pencillinases and thus it 
is effective against penicillin-resistant staphylococci. When 
given intravenously, its dosage may be increased to 2 g qds 
in staphylococcal bacteremia or osteomyelitis.
Erythromycin and clarithromycin
They have a similar spectrum to penicillin and are thus useful 
against staphylococci and streptococci in patients who are 
allergic to penicillin. There is an increased risk of myosi-
tis and rhabdomyolysis if the patient is on statin therapy. 
Thus, statin therapy may be stopped for the duration of 
erythromycin therapy. If the patient develops intolerance to 
erythromycin, particularly gastrointestinal side-effects, then 
clarithromycin may be used.
Fucidin
This is active against penicillin-resistant staphylococci. 
It has good bone penetration and is useful in osteomyelitis. 
Resistance to it develops quickly if it is given alone and 
therefore it should be given with another anti-staphylococcal 
agent. It is useful in combination therapy to treat MRSA 
infections. Liver function should be monitored if therapy 
is prolonged and it should be given with caution in patients 
with liver disease.
Doxycycline
This antibiotic can be used in treating MRSA infections. It 
should be used with caution in patients with hepatic impairment.
Rifampicin
This is active against staphylococci and streptococci and 
has good soft tissue and bone penetration. Patients should 
be warned that if they develop nausea, vomiting or malaise 
they should report this immediately as it may reflect liver 
dysfunction which is a well-described but rare side-effect of 
rifampicin therapy. It should be given with caution in patients 
with existing liver disease. Patients should be warned that 
their body secretions will turn red. Rifampicin should not be 
given alone because resistance can develop rapidly.
Clindamycin
This has very good soft tissue and bone penetration and is 
active against staphylococci, streptococci and anaerobes 
including B. fragilis. However, historically it has been linked 
with antibiotic associated colitis caused by Clostridium 
difficile infections although this can occur with many 
antibiotics.
Vancomycin
This is active against Gram-positive organisms and is usually 
used for MRSA infections. Blood levels should be monitored 
and trough levels should not be less than 15 mg/L.
Teicoplanin
This is a glycopeptide antibiotic which is active against 
Gram-positive organisms including MRSA. It can be given 
intravenously but also intramuscularly. This is a convenient 
therapy to be given at home.
Linezolid
Linezolid is active against Gram-positive organisms, including 
MRSA and vancomycin-resistant enterococci. It can be given 
orally or intravenously. It may cause marrow suppression 
and regular platelet counts are advisable. It should not be 
given for more than 28 days. Linezolid has been shown to be 
superior to co-amoxiclav (amoxicillin/clavulanic acid) and 
ampicillin/sulbactam for diabetic foot infections with and 
without osteomyelitis.17 It has also been shown to be at least 
equivalent to vancomycin in treating soft tissue infections and 
superior to vancomycin where the pathogen is MRSA.27
Daptomycin
Daptomycin is a novel cyclic lipopeptide with activity against 
a large number of resistant Gram-positive pathogens including 
MRSA, VRE and glycopeptide intermediate-susceptible 
S. aureus (GISA). It is given intravenously and has good 
soft tissue penetration. Weekly creatine phosphokinase levels 
should be monitored.28,29 The clinical and microbiological 
efficacy and safety of daptomycin were similar to those of 
commonly used comparator antibiotics for treating infected 
diabetic foot ulcers caused by Gram-positive pathogens. This 
was demonstrated in a randomized, controlled trial comparing 
daptomycin with vancomycin or semi-synthetic penicillins 
for complicated skin and skin-structure infections.30
Quinupristin/dalfopristin
This is a combination of the two antibiotics quinupristin and 
dalfopristin which work synergistically against Gram-positive 
organisms including MRSA.Vascular Health and Risk Management 2009:5 957
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Trimethoprim
It has reasonable soft tissue penetration and is active against 
Gram-positive and Gram-negative bacteria. It is also useful 
in combination therapy against MRSA.
Tigecycline
This is a glycylcycline antibiotic that is structurally similar 
to tetracycline antibiotics. Tigecycline was active against 
83.7% of all the strains against bacterial strains isolated 
from diabetic foot infections, especially Gram-positive cocci 
(97.3%), in particular MRSA (96%), Enterobacteriaceae 
(88.5%) and anaerobes (100%). Exclusively Pseudomonas 
and Proteae were not covered by this antibiotic.31
Antibiotics used mainly against 
Gram-negative organisms
Ciprofloxacin
This is a useful quinolone antibiotic active against 
Gram-negative organisms and has good soft tissue and 
bone penetration. It has only moderate activity against 
Gram-positive organisms. It is relatively well tolerated 
but occasionally can give neurological side-effects and 
can rarely predispose to hypoglycemia in certain patients. 
Other quinolones include levofloxacin and moxofloxacin. 
Moxifloxacin, a broad-spectrum fluoroquinolone which can be 
administered by either intravenous or oral routes. To assess the 
efficacy of moxifloxacin for treating diabetic foot infections, 
a subset of diabetic patients with these infections who were 
enrolled in a prospective, double-blind study that compared 
the efficacy of moxifloxacin with piperacillin/tazobactam 
and amoxicillin/clavulanate were analyzed. Intravenous ± 
oral moxifloxacin was as effective as intravenous piperacillin/
tazobactam ± amoxicillin/clavulanate.32
Septrin
This is a combination of trimethoprim and sulphmethoxazole 
and is occasionally used to treat resistant Gram-negative 
organisms such as Stenotrophomonas maltophilia but should 
only be used if other antibiotics against Gram-negative 
organisms are not appropriate.
Ceftriaxone
This is a useful antibiotic that can be given either intrave-
nously or intramuscularly when it is administered as 1 g in 
3.5 mL of 1% lignocaine. It needs to be given only once a 
day. This can be given in the community on a once daily basis. 
It has a wide spectrum of activity but is not active against 
MRSA or Pseudomonas.
Ceftazidime
This is useful as an initial agent to cover Gram-negative 
infections as it is usually active against Pseudomonas. If the 
dosage is not reduced in renal impairment, then the patient 
may develop muscular twitching and even fits. Penetration 
of ceftazidime into bone from severely ischemic limbs is 
satisfactory.33 Ten patients received 2000 mg of ceftazidime 
intravenously before undergoing lower-extremity amputation 
for ischemia. Bone and plasma concentrations were deter-
mined by HPLC. The bone concentrations were corrected for 
blood contamination. In all but one sample ceftazidime was 
detectable. These data indicate that ceftazidime penetrates 
into bone of severely ischemic limbs.
Piperacillin/tazobactam
This antibiotic is given intravenously and has a wide spectrum 
of activity including Gram-positive and Gram-negative 
organisms including Pseudomonas and anaerobes. It may 
be useful against bacteria with extended spectrum beta-
lactamases. In an open-label, randomized study comparing 
efficacy and safety of intravenous piperacillin/tazobactam 
(P/T) and ampicillin/sulbactam (A/S), clinical efficacy rates 
(cure or improvement) were statistically equivalent overall 
(81% for P/T vs 83.1% for A/S), and median duration of 
treatment was similar in the clinically evaluable populations 
(9 days for P/T, 10 days for A/S).34
Ticarcillin/clavulanic acid
This is given intravenously and is active against Pseudomonas, 
and other Gram-negative bacteria including Proteus spp. 
and B. fragilis.
imipenem with cilastin
This is a carbapenem with broad spectrum activity against 
Gram-positive and Gram-negative organisms including 
anaerobes. Imipenem is partly inactivated in the kidney and 
this is blocked by cilastin. It should be used with caution in 
renal failure as it may cause fits.
Meropenem
It is a bactericidal broad-spectrum carbapenem antibiotic that 
inhibits cell-wall synthesis. It is effective against most Gram-
positive and Gram-negative bacteria including Pseudomonas. 
It has slightly increased activity against Gram-negative 
species and slightly decreased activity against staphylococci 
and streptococci compared with imipenem. It is also useful 
against bacteria with extended spectrum beta lactamases 
(ESBLs). Meropenem is given intravenously and has less Vascular Health and Risk Management 2009:5 958
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frequently caused central nervous system side-effects, 
including fits, compared with imipenem.
Ertapenem
This is a carbapenem given once daily and is useful against 
Gram-positive and Gram-negative organisms and also anaer-
obes. Bactericidal activity results from inhibition of cell wall 
synthesis and is mediated through ertapenem binding to 
penicillin binding proteins. It is stable against hydrolysis by 
various beta-lactamases, including penicillinases, cepha-
losporinases and extended spectrum beta-lactamases. 
It is not active against Pseudomonas, enterococci or against 
Acinetobacter. It is useful against bacteria with ESBLs and 
AmpC-producing Gram-negative bacteria. It is generally 
given to adults as a 1 g dose, once a day, by intravenous 
infusion or intramuscular injection. It may be given intra-
muscularly as 1 g diluted with 3.2 mL of 1% lidocaine.
In a recent study ertapenem was shown to be equivalent 
in action with piperacillin/tazobactam in treating infected 
diabetic feet.26 In the SIDESTEP study, 586 patients were 
randomized into two treatment groups to receive intra-
venously either ertapenem 1 g once daily (n = 295) or 
piperacillin/tazobactam 3.375 g every 6 hours (n = 291) 
for a minimum of 5 days with the option to switch to oral 
amoxicillin/clavulanate for a total of 5 to 28 days of treatment 
(parenteral and oral). Patients were assessed by their clinical 
response between treatment groups at the 10-day post therapy 
follow-up visit. All patients were eligible to receive appro-
priate adjunctive treatment methods, such as debridement, 
and most patients received these treatments. Investigators 
had the option to add open-label vancomycin if enterococci 
or MRSA were among the pathogens isolated or if patients 
had a history of MRSA infection and additional therapy was 
indicated in the opinion of the investigator. Of those patients 
described as evaluable (ertapenem n = 204; piperacillin/
tazobactam n = 202), 75.0% of the patients taking ertapenem 
had a favorable clinical response compared to 70.8% of the 
patients taking piperacillin/tazobactam (CI = 95%). Rates 
of favorable microbiological responses and adverse events 
were also similar between the two treatment groups.
An economic analysis of treatment of diabetic foot infec-
tions showed that, compared with piperacillin-tazobactam 
given 4 times daily iv, ertapenem given once daily was asso-
ciated with lower drug acquisition and supply costs and less 
time and labor were devoted to preparation and administration 
of iv therapy.35 A cost-minimization analysis was conducted 
on the drug-dosing data of the subset of patients enrolled in 
the double-blind randomized trial who were treated solely as 
inpatients and were clinically evaluable at final assessment 
(n = 99). Cost per dose was calculated from (a) average 
hospital acquisition price per dose for ertapenem (US$40.52) 
or piperacillin/tazobactam (US$13.58), (b) average US 
wages and benefits for labor, based on 9 published time-
and-motion studies of iv antibiotic preparation and admin-
istration (US$3.10), and (c) consumable supplies, using a 
40% discount off the manufacturer list price (US$2.90). 
For each patient, the actual number of antibiotic doses 
given was multiplied by total cost per dose. There were no 
significant differences between antibiotic groups with respect 
to patient demographics, percentage with a severe wound, 
and mean days of iv therapy. Compared with piperacillin/
tazobactam, patients treated with ertapenem received 
significantly fewer mean doses (25.5 vs 7.5; P  0.0001) 
and lower antibiotic-related costs (US$502.76 vs US$355.55, 
respectively; P  0.001). The US$147.21 difference 
between groups accounts for approximately 3% of total 
hospital Medicare reimbursements for these infections. 
Compared with piperacillin/tazobactam given 4 times daily 
iv, ertapenem given once daily iv was associated with lower 
drug acquisition and supply costs and less time and labor 
devoted to preparation and administration of iv therapy.
A further study quantified the penetration of ertapenem 
into bone and synovial tissue. In an open-label study eighteen 
patients who were undergoing elective total hip replacement 
received a single, parenteral, 1 g dose of ertapenem.36 One 
serum, 1 cortical and cancellous bone and 1 synovial tissue 
sample was collected per patient. The median (interquartile 
range, IQR) serum concentrations of ertapenem were 70.1 
(56.1 to 75.9), 10.0 (9.1 to 11.2) and 2.6 mg/L (2.3 to 3.0), 
respectively, at the different time points. The median (IQR) 
cancellous bone tissue concentrations were 13.2 (10.2 to 
14.8), 1.9 (1.7 to 2.1) and 0.6 µg/g (0.4 to 0.6) at the different 
time points, corresponding to a median (IQR) tissue/serum 
penetration ratio of 0.19 (0.18 to 0.23). The median (IQR) 
cortical bone tissue concentrations were 8.0 (6.5 to 9.5), 
1.3 (1.2 to 1.3) and 0.3 µg/g (0.3 to 0.4) at the different 
time points, corresponding to a median (IQR) tissue/serum 
penetration ratio of 0.13 (0.12 to 0.14). The median (IQR) 
synovial tissue concentrations were 26.2 µg/g (22.7 to 28.4), 
4.0 mg/L (3.7 to 4.4) and 1.0 mg/L (0.9 to 1.2) at the different 
time points, corresponding to a median (IQR) tissue/serum 
penetration ratio of 0.41 (0.39 to 0.42). Thus the concentra-
tions after an ertapenem 1 g dose achieved in cancellous and 
cortical bone tissue and in synovial tissue were greater than 
the minimum inhibitory concentrations (MIC) 90 for most 
aerobic organisms for 24 hours, and for 12 to 24 hours for Vascular Health and Risk Management 2009:5 959
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anaerobic bacteria in healthy volunteers undergoing total 
hip replacement.
For localized organ or tissue infections, drug concentrations 
in the interstitial space rather than in serum determine the 
clinical outcome of antimicrobial therapy. One study investi-
gated ertapenem penetration into suction-induced skin blister 
fluids in 12 healthy young volunteers.37 Drug concentrations 
in skin blister fluids exceeded 4 mg/L (the MIC at which 
90% of isolates tested are eliminated) throughout the entire 
dosing interval of 24 hours. The area under the concentration-
time curve for 0- to 24-hour ratio of blister fluid to plasma 
was 61% (90% CI, 56, 65%) suggesting good blister 
penetration. A microdialysis study was conducted to measure 
free, protein-unbound ertapenem concentrations in muscle 
and subcutaneous tissue.38 Ertapenem concentrations in 
plasma reached a maximum (Cmax) of 103.3 ± 26.3 mg/L, a 
terminal elimination half-life (t1/2) of 3.8 ± 0.6 hours and an 
AUC0– of 359.7 ± 66.5 mg⋅h/L. Mean peak concentrations 
of free, protein-unbound ertapenem in interstitial space 
fluid of skeletal muscle and subcutaneous adipose tissue 
were much lower (Cmax = 6.7 ± 4.1 and 4.0 ± 1.6 mg/L, 
respectively). This degree of tissue distribution is consistent 
with high concentration-dependent plasma protein bind-
ing of ertapenem (84% to 96%). AUC0– values for both 
muscle and adipose tissue were lower as well (39.7 ± 24.8 
and 18.6 ± 4.6 mg⋅h/L). However, unbound interstitial fluid 
concentrations exceeded MIC90 values for the important skin 
and skin structure infection (SSSI) pathogens for 7 (subcutis) 
and 10 hours (muscle) after dosing. Penetration of ertapenem 
into skeletal muscle and subcutaneous adipose tissue in 
healthy volunteers measured by in vivo microdialysis was 
thus satisfactory.
Tigecycline
As well as its usefulness in infections caused by Gram-
positive organisms, including MRSA, S. aureus, vancomycin-
resistant enterococci and streptococci, it is also active against 
Gram-negative organisms including ESBLs and anaerobes 
including B. fragilis. Strains of Proteus spp. and P. eruginosa 
may be resistant. Nausea and vomiting may occur particularly 
as side-effects.
Aminoglycosides
These include amikacin, gentamicin, netilmicin and tobramycin. 
Gentamicin is the aminoglycoside of choice in the UK. 
It is active against some Gram-positive organisms and 
many Gram-negative organisms. Important side-effects 
are ototoxicity and nephrotoxicity. These side-effects are 
dose-related and thus extreme care should be taken with 
dosage. Gentamicin should be administered with strict blood 
level monitoring and the trough level should be less than 
1 mg/L. The objective of aminoglycoside treatment is to 
obtain quickly a high peak serum level as the mode of action 
of the agents is concentration dependent.
Antibiotics used against anaerobic 
organisms
Metronidazole is useful against anaerobic bacteria. Patients 
must be warned not to take alcohol. Clindamycin and 
co-amoxiclav (amoxicillin/clavulanic acid) also have anti-
anaerobic activity. Meropenem, piperacillin/tazobactam and 
ertapenem are also active against anaerobes.
Duration of antibiotic therapy
Patients with infected wounds require early and careful 
follow-up observation to ensure that the selected medical 
and surgical treatment regimens have been appropriate and 
effective. Antibiotic therapy should be continued until there 
is evidence that the infection has resolved but not necessarily 
until a wound has healed. The IDSA guidelines have made 
the following suggestions for the duration of antibiotic 
therapy as follows: for mild infections, 1 to 2 weeks usually 
suffices, but some require an additional 1 to 2 weeks; 
for moderate and severe infections, usually 2 to 4 weeks 
is sufficient, depending on the structures involved, the 
adequacy of debridement, the type of soft-tissue wound 
cover, and wound vascularity.
Antibiotics in patients with renal 
or liver impairment
It is ideal to perform renal and liver function tests before 
starting antibiotic therapy particularly intravenous therapy. 
These will provide baseline values and also alert the clinician 
to select appropriate antibiotics if renal or liver impairment 
is present. Renal impairment is common in diabetic foot 
patients, and antibiotics can give rise to problems in diabetic 
patients with reduced renal function for the following 
reasons:
•  Failure to excrete a drug or its metabolites may lead to 
toxicity.
•  Sensitivity to some drugs is enhanced even if elimination 
is unimpaired.
•  Many side-effects are badly tolerated by people in end-
stage renal failure.
•  Some drugs cease to be effective when renal function is 
impaired.Vascular Health and Risk Management 2009:5 960
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Many of these problems can be avoided by reducing the 
dose or by using alternative antibiotics. Tables indicating 
dosage of antibiotics in renal impairment should be 
consulted.11 Nephrotoxic antibiotics include the aminogly-
cosides. Fucidin, rifampicin and doxycycline should be 
given with caution to patients with liver imparment and 
serial liver function tests should be performed.
Surveillance for side-effects of antibiotics
When prescribing antibiotics, it is important to keep a 
very close surveillance for side-effects particularly skin 
rashes and gut reactions.
Dermatological drug reactions are self-limited diseases 
and therefore, generally treatment is symptomatic. Prompt 
diagnosis and early withdrawal of all suspect drugs are the 
most important steps. Severe skin reactions include toxic 
epidermal necrolysis, Stevens-Johnson syndrome and DRESS 
syndrome (Drug Rash [or Reaction] with Eosinophilia and 
Systemic Symptoms).39 The symptoms of DRESS syndrome 
usually begin 1 to 8 weeks after exposure to the offending 
drug. Classic symptoms are rash, fever, lymphadenopathy and 
involvement of one or more internal organs. The rash is an 
erythematous skin eruption often progressing to exfoliative 
dermatitis. It is treated with steroids but can have a mortality 
rate of about 10%.
Gut reactions can comprise nausea, vomiting, diarrhea 
and abdominal pain. If this does occur, it is advisable to 
stop the antibiotics, at least for a short period, to prevent the 
development of C. difficile colitis. Abdominal pain associ-
ated with diarrhoea and a raised white blood cell count and 
fever suggests clostridium difficile infection. Stools should 
be sent for culture but therapy should be started immediately 
with either vancomycin 125 mg qds orally or metronidazole 
400 mg tds orally. It is important to note that intravenous 
vancomycin is not active in the gut against C. difficile and 
neither does intravenous metronidazole have a major effect on 
this organism. The patient should also be given live yoghurt. 
Acidophilus tablets can also be given to restore the intestinal 
bacterial flora. In severe cases of diarrhea, patients may 
need hospitalization and intravenous fluids. If the patient 
does not respond to these conservative measures then a 
surgical opinion as to the necessity for a colectomy should 
be obtained. Recently, new strains of C. difficile appear to be 
more virulent, with ability to produce greater quantities of 
toxins. PCR ribotype 027 produces much more of the toxins 
than most other types because a mutation has knocked out 
the gene that normally restricts toxin production. It causes 
a greater proportion of severe disease and appears to have a 
higher mortality. It also seems to be particularly capable of 
spreading between patients.
Adjunctive therapies
Granulocyte colony stimulating factor (G-CSF) specifically 
enhances neutrophil funbction in diabetes and several inves-
tigators have explored its use as an adjunct in the treatmemt 
of diabetic foot infections.40 A recent Cochrane review has 
concluded that adjunctive G-CSF treatment in people with 
a diabetic foot infection, including infected ulcers, did not 
appear to increase the likelihood of resolution of infection 
or healing of the foot ulcer. However, it did seem to reduce 
the need for surgical interventions, especially amputations, 
and the duration of hospitalization. The authors concluded 
that “Clinicians might consider adding G-CSF to the usual 
treatment of diabetic foot infections, especially in patients 
with a limb-threatening infection, but it is not clear which 
patients might benefit.”40
Systemic hyperbaric oxygen therapy may be considered 
in an individual with severe infected diabetic foot ulcers with 
full thickness gangrene or abscess, or with a large infected 
ulcer that has not healed in over 30 days.41 In a systematic 
review evaluating published clinical evidence of the efficacy 
of hyperbaric oxygen therapy for wound healing and limb 
salvage it was noted that for patients with diabetic foot ulcers 
complicated by surgical infection, hyperbaric oxygen reduced 
the chances of amputation (odds ratio 0.242, 95% CI 0.137 
to 0.428) and improved the chance of healing (odds ratio 
9.992, 95% CI 3.972 to 25.132).42
Predictors of unfavorable outcomes
To aid clinicians in selecting the appropriate approach 
for treating patients with diabetic foot infections, a recent 
study investigated whether any baseline clinical findings 
predicted an unfavorable clinical outcome.43 Using data 
from a large, prospective treatment trial of diabetic foot 
infections (SIDESTEP), the association between clinical 
treatment failure and baseline history, physical and labora-
tory findings was assessed by univariate and multivariate 
logistic regression analyses. Among 402 patients clinically 
evaluable 10 days after completing antibiotic therapy, base-
line factors significantly (P  0.05) associated by univariate 
analysis with treatment failure were “severe” (vs “moderate”) 
University of Texas (UT) wound grade; elevated white blood 
cell count, C-reactive protein or erythrocyte sedimentation 
rate; high wound severity score; inpatient treatment; low 
serum albumin; male sex; and skin temperature of affected 
foot 10 °C above that of unaffected foot. By multivariate Vascular Health and Risk Management 2009:5 961
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logistic regression only severe UT wound grade (odds 
ratio 2.1) and elevated white blood cell count (odds ratio 1.7) 
remained statistically significant. Clinical failure rates were 
46% for patients with both risk factors compared with 10% 
for patients with no risk factors and 16% to 17% for patients 
with one risk factor. Increased white blood cell count and 
severe UT wound grade at baseline, but not other features, 
were significant independent and additive risk factors for 
clinical failure in patients treated for a diabetic foot.
Debridement
Antibiotics alone may be unable to control infection and it 
is necessary to decide whether debridement or adjunctive 
surgery is necessary.44 Patients with localized and spread-
ing infection usually undergo outpatient sharp debridement 
to remove callus and allow drainage. In patients with severe 
infection, the foot should be urgently assessed as to the neces-
sity for surgical debridement.10 Early surgical intervention 
of the affected site is usually necessary as an integral part of 
infection management. This may include simple debridement 
of the soft tissues, wide incision and drainage of the pedal 
compartments, or open amputation to eliminate extensive 
areas of infection. Although initial drainage procedures can 
be done at the bedside for neuropathic patients, most require 
thorough debridement in the operating room. Infected tissue 
should be sent for culture after debridement. Even very ill 
patients should be considered for urgent incision, drainage, 
and debridement procedures, because their illness is directly 
attributable to the infection severity.
The definite indications for urgent surgical intervention 
are:
•  A large area of infected sloughy tissue.
•  Localized fluctuance and expression of pus.
•  Crepitus with gas in the soft tissues on X-ray.
•  Blue or purplish discoloration of the skin.
Osteomyelitis
Classically, the treatment of osteomyelitis is surgical removal 
of bone. But long-term suppressive antibiotic therapy is also 
used.45 As osteomyelitis is usually associated with an infected 
ulcer and cellulitis, wide spectrum antibiotics should be 
initially given. On review, antibiotic selection is guided by the 
results of cultures. Ideally bone culture should be carried out 
but this is not always practical especially in ischemic feet.46 
Bone fragments in the base of the wound may be removed 
as in “office” debridement and then be sent for culture. It is 
useful to choose antibiotics with good bone penetration such 
as sodium fusidate, rifampicin clindamycin and ciprofloxacin. 
Combinations of antibiotics have also been used including 
rifampicin and ofloxacin. Antibiotics should be given for 
at least 12 weeks. Such therapy is often successful with 
resolution of cellulitis and healing of the ulcer.47 A recent 
report noted that diabetic foot osteomyelitis was effectively 
managed with oral antimicrobial therapy with or without 
limited “office” debridement in most cases.48 However, 
if after 6 months’ treatment, it is still possible to probe to 
bone, then operative resection may be necessary. Although 
urgent surgery is indicated in some patients, non-surgical 
management of those without limb-threatening infection is 
associated with a high rate of apparent remission.49
Revascularization
It is important to explore the possibility of revascularization 
in the infected neuroischemic foot. Improvement of perfusion 
will not only help to control infection, but will also promote 
healing of the wound if operative debridement is necessary. 
Initially, duplex angiography should be carried out to detect 
the presence of stenoses or occlusions which then may be 
amenable to angioplasty or bypass.
Metabolic control
In severe infections, considerable metabolic decompensation 
may occur. Full resuscitation is urgently required with intra-
venous fluids and intravenous insulin sliding scale which is 
often necessary to achieve good blood glucose control whilst 
the patient is infected. Critically ill patients who require 
surgery should usually be stabilized before transfer to the 
operating theater, although surgery should usually not be 
delayed for 48 hours after presentation to the hospital.
Conclusion
The development of infection in the diabetic foot constitutes 
a foot care emergency, which requires urgent referral to a 
specialized foot-care team. The underlying principle is to 
detect the bacteria responsible and treat aggressively.
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